DOCSLIB.ORG

00A-Tytulowe.Vp:Corelventura

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
00A-Tytulowe.Vp:Corelventura SOCIETY OF ECOLOGICAL CHEMISTRY AND ENGINEERING ECOLOGICAL CHEMISTRY AND ENGINEERING A CHEMIA I IN¯YNIERIA EKOLOGICZNA A Vol. 19 No. 10 OPOLE 2012 EDITORIAL COMMITTEE Witold Wac³awek (Society of Ecological Chemistry and Engineering, PL) – Editor-in-Chief Marina V. Frontasyeva (Joint Institute for Nuclear Research, Dubna, RU) – heavy metals and radionuclides Vasil Simeonov (University of Sofia, BG) – monitoring Maria Wac³awek (Opole University, PL) – alternative energy sources Barbara Wiœniowska-Kielian (University of Agriculture, Kraków, PL) – agricultural chemistry PROGRAMMING BOARD Witold Wac³awek (Society of Ecological Chemistry and Engineering, PL) – Chairman Jerzy Bartnicki (Meteorological Institute – DNMI, Oslo-Blindern, NO) Mykhaylo Bratychak (National University of Technology, Lviv, UA) Bogus³aw Buszewski (Nicolaus Copernicus University, Toruñ, PL) Eugenija Kupcinskiene (University of Agriculture, Kaunas, LT) Bernd Markert (International Graduate School [IHI], Zittau, DE) Nelson Marmiroli (University, Parma, IT) Jacek Namieœnik (University of Technology, Gdañsk, PL) Lucjan Paw³owski (University of Technology, Lublin, PL) Krzysztof J. Rudziñski (Institute of Physical Chemistry PAS, Warszawa, PL) Manfred Sager (Agency for Health and Food Safety, Vienna, AT) Mark R.D. Seaward (University of Bradford, UK) Pavlina Simeonova (Bulgarian Academy of Sciences, Sofia, BG) Petr Škarpa (Mendel University of Agriculture and Forestry, Brno, CZ) Piotr Tomasik (University of Agriculture, Kraków, PL) Roman Zarzycki (University of Technology, £ódŸ, PL) Ma³gorzata Rajfur (Opole University, PL) – Secretary STATISTICAL EDITORS W³adys³aw Kamiñski (Technical University, £ódŸ, PL) Zbigniew Ziembik (Opole University, Opole, PL) LANGUAGE EDITOR Ian Barnes (University of Wuppertal, Wuppertal, DE) EDITORIAL OFFICE Opole University ul. kard. B. Kominka 6, 45–032 OPOLE, PL phone: +48 77 455 91 49 email: [email protected] SECRETARY Ma³gorzata Rajfur phone: +48 77 401 60 42 email: [email protected] Copyright © by Society of Ecological Chemistry and Engineering, Opole Wersj¹ pierwotn¹ czasopisma jest wersja elektroniczna Ecological Chemistry and Engineering A / Chemia i In¿ynieria Ekologiczna A is partly financed by Ministry of Science and Higher Education, Warszawa ISSN 1898–6188 CONTENTS Wojciech BARAN, Ewa ADAMEK, Andrzej MAKOWSKI and Andrzej SOBCZAK – Assessment of Sulfonamides Occurrence in the Biosphere ........... 1153 Tomasz OLSZOWSKI – Particulate Matter and Elements – A Case Study of Land-Use Change “Before-After” on the Example of a New Road with Medium Traffic ..... 1173 Karolina FALKOWSKA, Tadeusz FILIPEK and Aleksandra BADORA – Dynamics of Air Pollution Emission from Nitrogen Plants “Pulawy” as the Result of Environmentally Friendly Actions .................... 1185 Jerzy SZYMONA – Chemical Substances in Natural Environment of Organic Farms . 1193 El¿bieta WO£EJKO, Urszula WYDRO, Robert CZUBASZEK, Andrzej BUTAREWICZ and Tadeusz £OBODA – Effects of Sewage Sludge on the Accumulation of Heavy Metals in Urban Soils ......................... 1199 Beata KUZIEMSKA and Stanis³aw KALEMBASA – Effect of Liming and Sewage Sludge Addition on the Distribution of the Fraction of Heavy Metals in Soil Contaminated with Nickel ........................ 1211 Marcin NIEMIEC, Monika ARASIMOWICZ and Barbara WIŒNIOWSKA-KIELIAN – Contents of Iron, Manganese and Zinc in the Sediments of Rainwater Reservoirs Situated along the National Road No. 4 ................... 1221 Monika ARASIMOWICZ, Marcin NIEMIEC and Barbara WIŒNIOWSKA-KIELIAN – Post-Effect of Increasing Bottom Sediment Additives to the Substratum on Nickel Uptake by Plants ....................... 1229 Tomasz CZECH, Florian GAMBUŒ and Jerzy WIECZOREK – Spatial Distribution of Various Forms of Iron in Heavy Metal Polluted Soils ............ 1239 Florian GAMBUŒ, Jerzy WIECZOREK and Tomasz CZECH – Changes of Heavy Metal Contents in Sludge from Selected Treatment Plants in the Western Malopolska Region in 1995–2009 ..................... 1247 Anna CHRZAN and Maria MARKO-WOR£OWSKA – Content of Heavy Metals in Soil and in Pine Bark in Skalki Twardowskiego Landscape Park in Krakow .... 1255 Beata ADAMKIEWICZ, Eugenia TÊGOWSKA, Barbara GRAJPEL and Justyna OLSZEWSKA – How Capsaicin Changes the Toxicity of Pyrethroids in American Cockroach (Periplaneta americana) .................... 1263 Joanna JARMU£-PIETRASZCZYK, Robert WRZESIEÑ, El¿bieta BUDZIÑSKA- -WRZESIEÑ and Marta KAMIONEK – Methods of Control of Synanthropic German Cockroach (Blattella germanica L.) in Various Urban Ecosystems ...... 1271 Ma³gorzata OSTROWSKA – Characteristics of Indicatory Algae against the Background of Physical-Chemical Conditions in Small Water Bodies on the Example of an Excavation in Biestrzynnik ..................... 1279 Wies³aw KOLAK – Evaluation of Possibility to Use Sodium Water Glasses Produced in Poland to Remove Ag+ Ions from Aqueous Media .......... 1289 VARIA Invitation for ECOpole ’12 Conference .................... 1299 Guide for Authors ............................ 1301 SPIS TREŒCI Wojciech BARAN, Ewa ADAMEK, Andrzej MAKOWSKI i Andrzej SOBCZAK – Ocena wystêpowania leków sulfonamidowych w biosferze ........... 1153 Tomasz OLSZOWSKI – Py³ zawieszony i pierwiastki – studium przypadku zmiany sposobu u¿ytkowania terenu na przyk³adzie nowej drogi o œrednim natê¿eniu ruchu ............................ 1173 Karolina FALKOWSKA, Tadeusz FILIPEK i Aleksandra BADORA – Dynamika emisji zanieczyszczeñ powietrza z Zak³adów Azotowych „Pu³awy” jako wynik dzia³añ proekologicznych ........................ 1185 Jerzy SZYMONA – Chemiczne substancje w œrodowisku przyrodniczym ekologicznych gospodarstw rolnych .......................... 1193 El¿bieta WO£EJKO, Urszula WYDRO, Robert CZUBASZEK, Andrzej BUTAREWICZ i Tadeusz £OBODA – Wp³yw stosowania osadów na gromadzenie siê metali ciê¿kich w miejskich glebach .......................... 1199 Beata KUZIEMSKA i Stanis³aw KALEMBASA – Wp³yw wapnowania i dodatku osadu œciekowego na rozmieszczenie frakcji wybranych metali ciê¿kich w glebie zanieczyszczonej niklem ........................ 1211 Marcin NIEMIEC, Monika ARASIMOWICZ i Barbara WIŒNIOWSKA-KIELIAN – Zawartoœæ ¿elaza, manganu i cynku w osadach ze zbiorników wód deszczowych usytuowanych wzd³u¿ drogi krajowej nr 4 .................. 1221 Monika ARASIMOWICZ, Marcin NIEMIEC and Barbara WIŒNIOWSKA-KIELIAN – Nastêpczy wp³yw wzrastaj¹cych dodatków osadu dennego do pod³o¿a na pobranie niklu przez roœliny .......................... 1229 Tomasz CZECH, Florian GAMBUŒ i Jerzy WIECZOREK – Rozk³ad przestrzenny ró¿nych form ¿elaza w glebach zanieczyszczonych metalami ciê¿kimi ........ 1239 Florian GAMBUŒ, Jerzy WIECZOREK i Tomasz CZECH – Zmiany zawartoœci metali ciê¿kich w osadach z wybranych oczyszczalni œcieków zachodniej Ma³opolski w latach 1995–2009 .......................... 1247 Anna CHRZAN i Maria MARKO-WOR£OWSKA – Zawartoœæ metali ciê¿kich w glebie i korze sosny w Parku Krajobrazowym Ska³ki Twardowskiego w Krakowie ..... 1255 Beata ADAMKIEWICZ, Eugenia TÊGOWSKA, Barbara GRAJPEL i Justyna OLSZEWSKA – W jaki sposób kapsaicyna zmienia toksycznoœæ pyretroidów w stosunku do karaczana amerykañskiego (Periplaneta americana)......... 1263 Joanna JARMU£-PIETRASZCZYK, Robert WRZESIEÑ, El¿bieta BUDZIÑSKA- -WRZESIEÑ i Marta KAMIONEK – Metody kontroli i zwalczania synantropijnych karaczanów (Blattella germanica L.) w ró¿nych ekosystemach miejskich .............................. 1271 Ma³gorzata OSTROWSKA – Charakterystyka glonów wskaŸnikowych na tle warunków fizyczno-chemicznych w ma³ych zbiornikach wodnych na przyk³adzie wyrobiska w Biestrzynniku ........................... 1279 Wies³aw KOLAK – Ocena mo¿liwoœci wykorzystania krajowych szkie³ wodnych sodowych do usuwania jonów Ag+ z mediów wodnych ................. 1289 VARIA Invitation for ECOpole ’12 Conference .................... 1299 Guide for Authors ............................ 1301 DOI: 10.2428/ecea.2012.19(10)110 ECOL CHEM ENG A. 2012;19(10):1153–1171 Wojciech BARAN1*, Ewa ADAMEK1, Andrzej MAKOWSKI1 and Andrzej SOBCZAK1,2 ASSESSMENT OF SULFONAMIDES OCCURRENCE IN THE BIOSPHERE OCENA WYSTÊPOWANIA LEKÓW SULFONAMIDOWYCH W BIOSFERZE Abstract: Sulfonamides, derivatives of p-aminobenzenesulfonic acid, have been used in the treatment of patients with bacterial diseases since 1940s. According to the Anatomical Therapeutic Chemical Classifica- tion (ATC) they are included in a group of antibacterial agents, intended mainly for internal use, commonly known as antibiotics. Sulfonamides are also used as herbicides and feed additives in agriculture. It is estimated that their annual world consumption in veterinary medicine only can be up to 15 thousand Mg (tons). At present, sulfonamides are detected in almost 100 % of environmental samples which are checked from the point of view of antibiotics contents. Typically, the determined concentrations of sulfonamides are lower than mg × dm–3 but in liquid manure they were even detected at the 100 mg × kg–1 level. An environmental risk caused by sulfonamides, estimated based on their ecotoxicity, is not great. However, there are evidences that they take part in generating drug resistance of microorganisms. Newly arisen drugresistance genes can be transferred between different strains of bacteria, eg by conjugation. As a result, these genes may occur in pathogenic bacteria present in the ecosystems that have not previously been exposed to antibiotics. The aim of this paper was to present the problems connected with the occurrence of sulfonamides in different ecosystems. Based
Load more

Recommended publications
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]
  • Statistical Analysis Plan / Data Specifications the Risk of Acute Liver Injury Associated with the Use of Antibiotics. a Replica
    WP6 validation on methods involving an extended audience Statistical analysis plan / data specifications The risk of acute liver injury associated with the use of antibiotics. A replication study in the Utrecht Patient Oriented Database Version: July 11, 2013 Authors: Renate Udo, Marie L De Bruin Reviewers: Work package 6 members (David Irvine, Stephany Tcherny-Lessenot) 1 1. Context The study described in this protocol is performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium). The overall objective of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. Work package 6 “validation on methods involving an extended audience” aims to test the transferability/feasibility of methods developed in other WPs (in particular WP2 and WP5) in a range of data sources owned or managed by Consortium Partners or members of the Extended Audience. The specific aims of this study within WP6 are: to evaluate the external validity of the study protocol on the risk of acute liver injury associated with the use of antibiotics by replicating the study protocol in another database, to study the impact of case validation on the effect estimate for the association between antibiotic exposure and acute liver injury. Of the selected drug-adverse event pairs selected in PROTECT, this study will concentrate on the association between antibiotic use and acute liver injury. On this topic, two sub-studies are performed: a descriptive/outcome validation study and an association study. The descriptive/outcome validation study has been conducted within the Utrecht Patient Oriented Database (UPOD).
    [Show full text]
  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
    WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • 6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
    31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Evaluation of Sulfa Drugs Against Recombinant Pneumocystis Carinii Dihydropteroate Synthetase and in Vivo
    40s J. EUK. MICROBIOL., VOL. 43, NO. 5, SEPTEMBER4CTOBER 1996 Evaluation of Sulfa Drugs against Recombinant Pneumocystis carinii Dihydropteroate Synthetase and In vivo YU-LONG HONG,' PAUL HOSSLER,' MARILYN BARTLETT, * SHERRY QUEENER, 'JAMES SMITH' AND STEVEN MESHNICK' ,* 'Dept. of Epidemiology, Univ. of Michigan, Ann Arbor MI, and 'Dept. of Pathology and Lab. Medicine, Indiana Universiry School ofMedicine, Indianapolis, IN Sulfa drugs are potent and important anti-pneumocystis agents, Table 1. Effects of sulfa drugs on P. carinii infections in mice. but have a high incidence of adverse effects in AIDS patients. Drug- Dose Mean infection (SD) Although 15,000 sulfa drugs have been synthesized and dozens me/kdd(No.) G iem sa Silv er have been used in people, relatively few have been tested against P. Control 0 (20) 4.4 (0.2) 3.6 (0.1) carinii. In order to determine whether there are sulfa drugs which Therapy are better antipneumocystis agents than sulfamethoxazole and Sulfisoxazole 1.0 (10) 4.5 (0.1) 3.3 (0.1) dapsone, we have been testing sulfa drugs in vitro, against Sulfamethoxypyridazine 1.0 (10) 0.3 (0.1) 0.2 (0.1) recombinant P. carinii dihydropteroate synthetase, and in vivo. Sulfamethoxazole 1.0 (10) 0.1 (0.0) 0.1 (0.0) MATERIALS AND METHODS. Immunosuppression of latently infected rats, isolation of organisms, and enzyme and uptake Prophylaxis assays were performed as previously described (I). Rats were Sulfisoxazole 1.0 (10) 1.4 (0.3) 1.6 (0.2) administered drug continuously via their drinking water for the full Sulfamethoxypyridazine 1.0 (10) 0.1 (0.1) 0.1 (0.1) 6 weeks of immunosuppression.
    [Show full text]